Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Discovering The Root Causes of Diseases

September 15, 2023 0

Prohost Letter #457 Discovering The Root Causes of Diseases Biotech firms with solid scientific fundamentals …

Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia

September 12, 2023 0

Neurocrine Biosciences in the NEWS Today, Neurocrine Biosciences (NBIX) announced positive top-line data from Phase 3 …

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly

September 11, 2023 0

Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly Crinetics Pharmaceuticals (CRNX) announced that its oral and …

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

August 31, 2023 0

Alpine Immune Sciences Treating IgA nephropathy Alpine Immune Sciences (ALPN) announced a successful initiation of the …

Halozyme Therapeutics ENHANZE Reduces Roche’s Tecentriq® Treatment Time to 7 Minutes from 30-60

August 29, 2023 0

Halozyme Therapeutics in the NEWS Halozyme Therapeutics (HALO) announced today that the Medicines and Healthcare Products …

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

August 26, 2023 0

Exelixis in the NEWS Exelixis CABOMETYX is approved for the treatment of many cancers. The product …

Arcus Biosciences Participates in Multiple Upcoming Investor Conferences. The Stock is Boosted. See Also: Today’s Roche Press Release

August 23, 2023 0

Arcus Biosciences Arcus Biosciences (RCUS) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination …

Regeneron Pharmaceuticals EYLEA HD Approved by FDA for Wet Age-related Macular Degeneration, Diabetic Macular Edema and Diabetic Retinopathy

August 21, 2023 0

Regeneron Pharmaceuticals EYLEA HD Approved by the FDA Regeneron Pharmaceuticals (REGN) announced that the U.S. FDA has …

The Biotechnology Revolution: News from Nuvectis Pharma and Revolution Medicines Publication

August 20, 2023 0

Nuvectis Pharma Nuvectis Pharma (NVCT) is a biopharmaceutical company focused on developing innovative precision targeted drugs …

The U.S. FDA Approved Johnson & Johnson AKEEGA™ for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

August 15, 2023 0

Johnson & Johnson’s Janssen Pharmaceutical AKEEGA Johnson & Johnson (JNJ) owned Janssen Pharmaceutical announced that the U.S. …

Xenon Pharmaceuticals Reports 2Q 2023 Financial Results and Provides Corporate Update

August 15, 2023 0

Xenon Pharmaceuticals Q2 Financial Results On August 09, 2023 , Xenon Pharmaceuticals (XENE) reported financial results for …

Reminders About CymaBay Therapeutics and Jazz Pharmaceuticals Conference Calls Today at 4.30 PM

August 10, 2023 0

CymaBay Therapeutics and Jazz Pharmaceuticals Conference Call Info CymaBay Therapeutics: Hosting a Conference Call and Live …

TG Therapeutics Will Have An Important Conference Call at 8:30 AM Tomorrow, August 1st

July 31, 2023 0

TG Therapeutics Conference Call TG Therapeutics (TGTX) announced that, tomorrow, Tuesday, August 1, 2023, a conference …

ImmunoGen Reports Recent Progress and 2Q 2023 Financial Results. In Other News, Anna Berkenblit, MD, Senior VP and CMO Stepping Down from Her Position

July 31, 2023 0

ImmunoGen in the News WALTHAM, Mass.--(BUSINESS WIRE) --Jul. 31, 2023-- ImmunoGen (IMGN), a leader in the …

Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

July 26, 2023 0

Merck and Moderna Inc Announcement Merck (MRK) and Moderna Inc (MRNA . . . This content …

The U.S. FDA Approved BioMarin’s ROCTAVIANTM, the First and Only Gene Therapy for Adults with Severe Hemophilia A in the US

July 6, 2023 0

BioMarin Pharmaceutical US FDA Approval for ROCTAVIAN On June 30, 2023, BioMarin Pharmaceutical (BMRN) announced that …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Discovering The Root Causes of Diseases

Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

Halozyme Therapeutics ENHANZE Reduces Roche’s Tecentriq® Treatment Time to 7 Minutes from 30-60

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Arcus Biosciences Participates in Multiple Upcoming Investor Conferences. The Stock is Boosted. See Also: Today’s Roche Press Release

Regeneron Pharmaceuticals EYLEA HD Approved by FDA for Wet Age-related Macular Degeneration, Diabetic Macular Edema and Diabetic Retinopathy

The Biotechnology Revolution: News from Nuvectis Pharma and Revolution Medicines Publication

The U.S. FDA Approved Johnson & Johnson AKEEGA™ for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Xenon Pharmaceuticals Reports 2Q 2023 Financial Results and Provides Corporate Update

Reminders About CymaBay Therapeutics and Jazz Pharmaceuticals Conference Calls Today at 4.30 PM

TG Therapeutics Will Have An Important Conference Call at 8:30 AM Tomorrow, August 1st

ImmunoGen Reports Recent Progress and 2Q 2023 Financial Results. In Other News, Anna Berkenblit, MD, Senior VP and CMO Stepping Down from Her Position

Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma

Why Syndax and Incyte Traded UP in Today’s Early Morning

Halozyme Therapeutics’ Positive Results for Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Treating Cancers Resistant to ALL Drugs a Priority for Researchers. See What Merck and Kintara Have Done

Treatments for Untreatable Diseases

The U.S. FDA Approved BioMarin’s ROCTAVIANTM, the First and Only Gene Therapy for Adults with Severe Hemophilia A in the US